Tiziana Life Sciences is a Bermuda-incorporated clinical-stage biotech whose entire public-market identity now sits on a single nasal antibody and a single placebo-controlled readout. Intranasal foralumab is a fully human anti-CD3 monoclonal antibody designed to induce regulatory T cells in the lining of the nose and dampen microglial inflammation in the brain without the systemic toxicity of infused anti-CD3 drugs. The company deprioritized every other pipeline asset years ago, so the equity is not a diversified platform basket. It is a clock. The last patient in the INFORM-MS mid-stage trial received a first dose in late June, and management has pointed to an unblinding in late third quarter or early fourth quarter, with a planned presentation at the joint ACTRIMS and ECTRIMS meeting in Toronto in October.
The cash position is the other half of the same story. Year-end cash sat at $4 million against a going concern emphasis from the outside auditor. A January insider-led registered direct then added $9 million of gross proceeds. That raise, priced just above a dollar a share and paired with short-dated warrants that later expired out of the money, bought a path to the INFORM-MS unblinding. It did not buy a registrational program or a commercial infrastructure. Supportive open-label work is real and easy to over-read. An expanded-access cohort showed disability stabilization and meaningful fatigue improvement in a majority of treated patients, yet the company itself calls those figures a trend analysis rather than a statistically significant result. Separate PET images in the first three multiple system atrophy patients showed sizable reductions in tracer uptake in disease-relevant brain regions. Those images are consistent with a microglial-quieting mechanism. They still come from unblinded, single-digit samples that do not replace a placebo-controlled primary endpoint.
The market capitalizes the company at roughly $115 million, or many times year-end book equity, which means almost the entire capitalization is option value on foralumab. Shares trade under a dollar, inside a full-year range that ran from the mid-seventy-cent area to just over $2, and the founder still controls about one third of the register. The question the next several months resolve is whether INFORM-MS produces a clean, placebo-adjusted imaging and disability signal large enough to finance the next study on tolerable terms, or whether another going-concern raise arrives first at a price that transfers most of the remaining upside to new paper.